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Breakthrough pain in patients 
with chronic cancer pain followed 
by palliative care and pain clinic 
physicians — an observational 
study
Abstract
Background. Breakthrough pain (BtP) is common among patients suffering from cancer pain. The experi-
ence, knowledge and education of palliative care physicians or pain clinicans seems to be essential for proper 
diagnosis and treatment of breakthrough pain. Another key point is knowledge and behavior of patients suf-
fering the breakthrough pain episodes. The aim of this study was to determine, whether patients suffering 
the cancer chronic pain are being informed by physicians working in palliative care outpatients and pain 
clinics about BtP occurrence and treatment, as well as how patients are utilizing the rescue medications. 
Material and methods. Six hundred seventy eight patients participated in the study. The common demo-
graphic (age, sex), disease-related, background pain (including mode and effectiveness of treatment) data 
were collected. The information about breakthrough pain occurrence, number of episodes, BtP manage-
ment, frequency of rescue medications dosing and effectiveness of these medications were also collected. 
Results. Over 75% of them had been prescribed strong opioid and almost 25% of the patients — weak opioid. 
58% had uncontrolled background pain. BtP was reported by 69,3% of these patients, most commonly one 
or two episodes per day. Only 3% of patients experienced more than 4 episodes a day. As a rescue medica-
tion patients usually used morphine, followed by nonsteroidal antiinflamatory drugs and paracetamol, but 
statistically not every time they experienced the BtP. 
Conclusion. This study confirmed that patients followed by palliative care outpatients and pain clinics receive 
information about background and breakthrough pain, and are well orientated in pain medications. The 
problem emerges in proper utilization of rescue medications, most commonly prescribed as oral.
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Introduction
The known data show, that around 25 mil-
ions people worldwide lives with cancer disease 
nowadays. 30–40% of them, in the time of cancer 
diagnose, are suffering of pain, with the number 
growing along with the course of the disease up to 
70–90% patients in the end of life period [1]. Break-
through pain (BtP) is a quite common phenom-
enon in a cancer patients population. Its incidence 
is being ranged up to 40–80% [2]. Breakthrough 
pain has been defined as a transitory exacerba-
tion of pain that occurs either spontaneously or in 
relation to a trigger despite adequately controlled 
background pain. It is usually managed with short 
acting opioid drugs, known as rescue medications, 
added to routine analgesics administered “by the 
clock” [3]. Although BtP is not a seldom phenom-
enon, its diagnosis and treatment still leaves a lot 
to desired point. It seems that a crucial point decid-
ing of proper management of breakthrough pain 
remains education and knowledge of palliative care 
physicians and pain clinicans. Another key point 
is knowledge and behavior of patients suffering 
the breakthrough pain episodes. From the literature 
references and our own experience, patients do 
not follow the doctors’ prescriptions- do not take 
the right dose of rescue medication and not every 
time they experience the BtP episode [4–6]. The 
most common reasons for above situation are lack 
of  drug effect, adverse events or concerns about 
them, difficulties in taking the medication and 
lack of knowledge about certain medication [5, 6]. 
The aim of this study was to determine, whether 
patients suffering the cancer chronic pain are being 
informed by physicians working in palliative care 
outpatients and pain clinics about BtP occurrence 
and treatment, as well as how patients are utilizing 
the rescue medications. 
Material and methods
The study was conducted among the patients of 
palliative care outpatients and pain clinics in Poland 
(11 and 34 clinics respectively). The patients aged 18 
and over, with diagnose of cancer disease and suffer-
ing of cancer pain were recruited to the study. The 
only exclusion criterion for the study was patients’ 
cognitive impairment. 
Patients, during the outpatient visits, were ac-
complished the anonymous questionnaires in the 
period of two months of 2010 y. The questionnaire 
consisted of 12 questions. The common demo-
graphic (age, sex), disease-related, background pain 
(including mode and effectiveness of treatment) 
data were collected. The information about break-
through pain occurrence, number of episodes, pain 
management, frequency of rescue medications dos-
ing and effectiveness of these medications were 
also collected. 
The quantitative data from the question-
naires has been analyzed and the percentage val-
ues of patients declared answers were shown. 
Tables were drawn using the graphic computer 
programs. 
Results
Six hundred seventy eight patients participated 
in the study (347 males, 331 females). The median 
age was 63 years (range 25–86 years). All of the 
patients were receiving analgesic drugs for their 
background pain. Over 75% of them had been 
prescribed strong opioid (mainly morphine, fenta-
nyl and buprenorphine), and almost 25% of the 
patients — weak opioid (tramadol, dihydrocodeine 
and codeine). Additionally more than 60% of the 
patients were receiving co-analgesic drugs like non-
steroidal antiinflamatory drugs (NSAIDs) or para-
cetamol (Table 1). 37.52% of the patients reported 
mean intensity of their background pain in last 
24 hours between 4 and 6 in a 11-point numeric 
rating scale (NRS, 0-10), while 21.3%  of them had 
pain intensity of 7 and more. 
Four hundred seventy (69.3%) of the patients had 
breakthrough pain episodes. More than half pa-
tients of this group declared 1 or 2 episodes of 
BtP in last 24 hours — 32% and 34% respectively. 
One fifth of the patients had three episodes of 
breakthrough pain, twice as much as ones having 
4 episodes. 3% of respondents declared more than 
4 episodes of BtP per day (Table 2). 29% of the 
patients used the rescue medication twice in the 
last 24 hours and almost the same percentage of 
patients used it once. Three and four times per day 
used the rescue medication 14.2% and 10% of the 
respondents respectively, and over four times — 8% 
of them. Almost 12% of the patients declared the 
different patterns of rescue medication utilization, 
like “once a day for three months” (Table 2). Of the 
patients experiencing BtP, as a main rescue medica-
tion, 70% had declared morphine, 20% — NSAIDs, 
15.4% — paracetamol and 11.3% — tramadol 
(Table 3). Most of the patients evaluated efficacy 
of used rescue medications in controlling epi-
sodes of breakthrough pain very well: 38.9% of the 
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patients evaluated these drugs as efficacious and 
15.1% as completely efficacious. Only 5.4% of the 
patients declared the BtP therapy as ineffective 
(Table 4).
Discussion   
Few hundreds patients cured by palliative care 
outpatients and pain clinics physicians due to chronic 
Table 1. Drugs used by patients to control background pain (more than one answer was possible) 
Analgesic used Number of answers Percentage of answers
Paracetamol 298 24
NSAIDs 508 41
Codeine 12 1
Dihydrocodeine 37 3
Tramadol 285 23
Morphine 670 54
Fentanyl 211 17
Buprenorphine 87 7
Methadone 0 0
Oxycodone 0 0
Table 3. Drugs used by patients to control BtP episodes (more than one answer was possible) 
Analgesic used Number of answers Percentage of answers
Paracetamol 105 15.4
NSAIDs 136 20
Codeine 7 1
Dihydrocodeine 2 0.3
Tramadol 77 11.3
Morphine 477 70
Fentanyl 2 0.3
Buprenorphine 3 0.5
Methadone 1 0.1
Oxycodone 0 0
Other 7 1
Table 2. Number of BtP episodes and rescue medication utilization for last 24 hours before questionnaire 
(group of patients experiencing any BtP episode)
Number of BtP 
episodes
Number 
of patients
Percentage 
of patients
Number of rescue 
medication 
utilization
Number 
of patients
Percentage 
of patients
1 150 32 1 × 126 26.8
2 160 34 2 × 136 29
3 94 20 3 × 67 14.2
4 52 11 4 × 47 10
> 4 14 3 > 4 × 38 8
Another answer 56 12
Sum 470 100 Sum 470 100
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cancer pain had participated in the study. All of the 
patients had been prescribed opioid drugs as back-
ground medication, both the strong (mostly) and 
weak ones. Unfortunately, almost 60% of the pa-
tients had uncontrolled background pain (as mean 
NRS pain intensity score for last 24 hours was 4 and 
more). Due to design of the questionnaire, we can 
not precisely explain the cause of that situation, 
nonetheless prescription of the improper drugs or 
improper doses might be the answer. It is very likely 
that patients with uncontrolled background pain 
may have significantly higher incidence of BtP epi-
sodes [7–10].
Almost 70% of respondents had episodes of BtP 
during last 24 hours before fulfilling the question-
naire. This is much higher percentage than shown 
in Spanish or Italian surveys on palliative care home 
and inpatient populations [7, 11]. On the other hand, 
similar number of patients suffering of breakthrough 
pain episodes may be found in British and American 
studies, where the percentage of patients with un-
controlled background pain was also significantly 
higher [6, 12, 13]. 
Most of the patients had declared one or at most 
two episodes of BtP a day. Only 15 patients had 
over four episodes. This highly variable number of 
episodes of BtP per day, so typical as a feature of 
that pain, is reflected in literature [7, 11]. In case of 
this study the question is whether the relatively small 
number of per day episodes of BtP in comparison 
with relatively poor control of background pain is not 
caused by patients’ problems with recognizing and 
distinguishing the episodes from background pain. 
The most common rescue medication prescribed 
to the patients was morphine. Another opioids used 
in management of BtP was tramadol and only individ-
ual patients chose fentanyl, codeine and buprenor-
phine. Interestingly, a number of patients (over 35%) 
were using formulations of NSAIDs and paracetamol 
as rescue medications. As answering the question 
about rescue medication, patients may have chosen 
few options, it is possible that physicians prescribed 
NSAID or paracetamol additionally to the opioid res-
cue medication or the patients used them without 
any doctors prescription. Actually, when analyzing 
that answers, it is reasonably to assume that great 
number of patients use only the analgesic ladder 
step one drugs as rescue medication despite having 
prescribed opioids to manage the background pain. 
This may be caused by lack of physicians’ precise 
knowledge of BtP phenomenon or inappropriate 
prescriptions or drugs dosing. 
Another problem is how patients are following 
the doctors’ prescriptions. The results of the study 
clearly confirmed that patients do not take rescue 
medication every time they experience the BtP epi-
sode. Among the most common reasons for not tak-
ing rescue medication is the fact that pain improved 
before the drug started to work (this has obvious jus-
tification in BtP characteristics and using mainly oral 
breakthrough medications) and low pain intensity 
[6, 14]. Especially this second one may be the most 
common reason for not taking the rescue medication 
or using non – opioid drugs. Moreover, the majority 
of patients mentioned, that their management of 
breakthrough pain is effective. 
Summarizing, it seems that patients followed by 
palliative care outpatients and pain clinics receive 
information about background and breakthrough 
pain, and are well orientated in pain medications. 
The problem emerges in proper utilization of rescue 
medications, most commonly prescribed as oral. 
Maybe introduction of novel products, given by the 
different routes, will improve the situation [14–17]. 
Nevertheless, these aims will only be successful, 
when both physicians and patients will receive prop-
er, targeted education about the management of 
breakthrough pain. 
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Table 4. Patients’ evaluation of BtP management efficacy
Evaluation of BtP management efficacy Number of patients Percentage of patients
Ineffective 25 5.4
Moderately efficacious 191 40.6
Efficacious 183 38.9
Completely efficacious 71 15.1
Sum 470 100
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